Results 201 to 210 of about 1,940,966 (390)

Dexmedetomidine suppresses glucose‐stimulated insulin secretion in pancreatic β‐cells

open access: yesFEBS Open Bio, Volume 15, Issue 4, Page 634-646, April 2025.
Dexmedetomidine decreases insulin release and affects glucose metabolism; however, the specific mechanism remains largely unknown. This study shows clinically relevant doses of dexmedetomidine suppressed glucose‐stimulated insulin secretion. There was no significant difference in oxygen consumption rate, intracellular ATP levels, or caspase‐3/7 ...
Munenori Kusunoki   +5 more
wiley   +1 more source

Comparative activity of dimethyl fumarate derivative IDMF in three models relevant to multiple sclerosis and psoriasis

open access: yesFEBS Open Bio, Volume 15, Issue 5, Page 754-762, May 2025.
IDMF is a derivative of dimethyl fumarate (DMF) with a unique therapeutic potential at the intersection of psoriasis and multiple sclerosis. Here, we demonstrate that it compares favorably with DMF and its other derivatives, such as Diroximel, in the zebrafish, microglia, and lymphocyte models.
Yulin He   +5 more
wiley   +1 more source

Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation

open access: yesFEBS Open Bio, Volume 15, Issue 5, Page 836-855, May 2025.
Osimertinib reduces angiogenesis and PDL1 expression in in ovo tumors, transforming them into ‘cold tumors’ with lower immune activity. Anatomopathological and transcriptomic analyses highlight its therapeutic impact on tumor biology. This study underscores osimertinib's potential to reshape the tumor microenvironment and provides insights into its ...
David Barthélémy   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy